The Use of Monoclonal Antibody Immunoconjugates in Cancer Therapy

  • Geoffrey A. Pietersz
  • Kenia Krauer
  • Ian F. C. McKenzie
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 353)


The conventional therapeutic approaches to breast cancer, including surgery, radiotherapy and cytotoxic drugs, has led to a certain degree of responsiveness which has not significantly changed in the last 20 years. Because of the high incidence of breast cancer, there is a real need to use additional forms of therapy which could potentially lead to a cure of this disease. In this light, new therapeutic approaches using antibodies (either alone or as immunoconjugates as discussed herein), or antigen (as in vaccination procedures) are receiving close attention. The current status of vaccines for breast cancer is considered elsewhere in this volume, and here we review the use of antibody based therapy. It should be noted that while antibodies are discussed in this chapter as a means of conveying toxic moieties to tumors, other carriers such as serum proteins (eg transferrin), cytokines (eg. IL-2) and other moieties have been used; these have been reviewed elsewhere1. At this time, there is some pessimism regarding the value of antibody immunoconjugates for the therapy of cancer, and at the outset we would like to dispel this pessimism for the following reasons: a) few, if any trials have progressed beyond Phase I/II and a formal comparison with other modes of therapy has not been done; b) as these are early studies, most of the patients used for therapeutic purposes had very large lesions and it would be most unlikely that complete responses could be obtained (as will be discussed below, it is our belief that immunoconjugates will find a place, and control the treatment of small metastic deposits arising from the treatment of large volume disease); c) the treatment of solid tumors usually has to be curtailed because of the occurrence of human anti-mouse antibody (HAMA) responses, and the maximum tolerated dose of immunoconjugate has rarely been achieved.


Breast Cancer Minimal Residual Disease Human Antibody Antibody Conjugate Murine Antibody 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    G.A. Pietersz, A. Rowland, M.J. Smyth and I.F.C. McKenzie, Conjugated antibodies: chemoimmunoconjugates, in: “Therapeutic Applications Of Monoclonal Antibodies In Cancer”, Ed. R.O. Dillman, Marcel-Dekker Inc, California In press (1992).Google Scholar
  2. 2.
    G.A. Pietersz, J. Kanellos and I.F.C. McKenzie, Novel synthesis and in vitro characterization of a disulfide linked ricin-monoclonal antibody conjugates devoid of galactose binding activity, Cancer Res. 48: 4469 (1988).PubMedGoogle Scholar
  3. 3.
    J. Kanellos, I.F.C. McKenzie and G.A. Pietersz, Intratumor therapy of solid tumors with the use of ricin-antibody conjugates, Immunol, and Cell Biol. 67: 89 (1989).CrossRefGoogle Scholar
  4. 4.
    P.D. Senter, P.M. Wallace, H.P. Svensson, D.E. Kerr, I. Hellstrom, and K.E. Hellstrom, Activation of prodrugs by antibody-enzyme conjugates, Adv. Exp. Med. Biol. 303:97 (1991).PubMedCrossRefGoogle Scholar
  5. 5.
    J.W. Uhr, R.J. Fulton, M.A. Till and E.S. Vitetta, Monoclonal antibodies as carriers of toxins, Prog. Clin. Biol. Res. 288: 403 (1989).PubMedGoogle Scholar
  6. 6.
    P. Vigeral, N. Chkoff, L. Chatenoud et al, Prophylactic use of OKT3 monoclonal antibody in cadaver kidney recipients: utilization of OKT3 as the sole immunosuppressive agent, Transplantation. 41: 730 (1986).PubMedCrossRefGoogle Scholar
  7. 7.
    R. Willemze, D.J. Richel, J.H. Falkenburg, G. Hale, H. Waldmann, F.E. Zaan et al, In vivo use of Campath-IG to prevent graft-vs-host disease and graft rejection after bone marrow transplantation, Bone Marrow Transpl. 9:255 (1992).Google Scholar
  8. 8.
    B.H. Peterson, S.V. Deherdt, D.W. Scheck and T.F. Bumol, The human immune response to KSl/4-desacetylvinblastine (Ly256787) and KSl/4-dacetylvinblastine hydrazide (Ly203728) in single and multiple dose clinical trials, Cancer Res. 51: 2286 (1991).Google Scholar
  9. 9.
    A. A. Epenetos (personal communication).Google Scholar
  10. 10.
    G.A. Pietersz, The linkage of cytotoxic drugs to monoclonal antibodies for the treatment of cancer, Bioconj. Chem. 1: 89 (1990).CrossRefGoogle Scholar
  11. 11.
    G.A. Pietersz, MJ. Smyth and I.F.C. McKenzie, Immunochemotherapy of a murine thymoma with idarubicin-monoclonal antibody conjugates, Cancer Res. 48: 926 (1988).PubMedGoogle Scholar
  12. 12.
    K.G. Krauer, R. Bell and G.A. Pietersz, Aminopterin-monoclonal antibody conjugates. Antitumor activity and toxicity, Drug Targeting and Delivery. In press (1992).Google Scholar
  13. 13.
    A. Goerlach, K.G. Krauer, I.F.C. McKenzie and G.A. Pietersz, In vitro antitumor activity of 5-fluoro-2-deoxyuridine-monoclonal antibody conjugates, Bioconj. Chem. 2: 96 (1991).CrossRefGoogle Scholar
  14. 14.
    G.A. Pietersz, K.G. Krauer, H. Holessis and I.F.C. McKenzie, Conjugation in vitro and in vivo efficacy of highly cytotoxic anti cancer drugs-aminopterin (AMN), 5-fluoro-2-deoxyuridine (5-FUDR) and podophyllotoxin, Abstract P-85 in “Proc. of 5th international conference on monoclonal antibody immunoconjugates for cancer”, Antib. Immunoconj. Radiopharm. 4:226 (1991).Google Scholar
  15. 15.
    G.A. Pietersz, MJ. Smyth and I.F.C. McKenzie, The use of anthracycline antibody complexes for specific antitumor therapy in: “Targeted Diagnosis And Therapy”, Ed J.D. Rodwell, Marcell Dekkerlnc, California, 1:25 (1988).Google Scholar
  16. 16.
    K.G. Krauer, I.F.C. McKenzie and G.A. Pietersz, The anti-tumor effect of 2’-deoxy-5’-fluorouridine conjugates against a murine thymoma and colon carcinoma xenografts, Cancer Res. 52: 132 (1992).PubMedGoogle Scholar
  17. 17.
    A.J. Rowland, I.F.C. McKenzie and G.A. Pietersz, Preclinical investigation of the antitumor effects of anti-CD 19-idarubicin immunoconjugates, Cancer Immunol. Immunother. Submitted (1992).Google Scholar
  18. 18.
    J. Kanellos, G.A. Pietersz, Z. Cunningham and I.F.C. McKenzie, Antitumor activity of aminopterin-monoclonal antibody conjugates; in vitro and in vivo comparison with methotrexate-monoclonal antibody conjugates, Immunol. Cell Biol. 65: 483 (1987).PubMedCrossRefGoogle Scholar
  19. 19.
    J.J. Tjandra, L. Ramadi and I.F.C. McKenzie, Development of human anti-murine antibody (HAMA) response in patients, Immunol. Cell Biol. 68: 367 (1990).PubMedCrossRefGoogle Scholar
  20. 20.
    M.J. Smyth, G.A. Pietersz and I.F.C. McKenzie, Use of vasoactive agents to increase tumor perfusion and the antitumor efficacy of drug-monoclonal antibody conjugates, J. Natl. Cancer Inst. 79: 1367 (1987).PubMedGoogle Scholar
  21. 21.
    S.M. Russell, K.G. Krauer, I.F.C. McKenzie and G.A. Pietersz, Effect of tumor necrosis factor on the antitumor efficacy and toxicity of aminopterin-monoclonal antibody conjugates. Parameters in optimization of therapy, Cancer Res. 50: 6028 (1990).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • Geoffrey A. Pietersz
    • 1
  • Kenia Krauer
    • 1
  • Ian F. C. McKenzie
    • 1
  1. 1.The Austin Research InstituteThe Austin HospitalHeidelbergAustralia

Personalised recommendations